DENVER–(BUSINESS WIRE)–EvoEndo®, Inc. (“EvoEndo”), a medical device company which developed a single use system that allows for unsedated Transnasal Endoscopy (TNE), has announced the completion of an $8.4 million Series A financing round led by founding investor TLP Investment Partners LLC (TLP) and including the Sunshine Charitable Foundation and the Jill and Paul Meister family. Proceeds from the financing will be used to support the initial commercial launch of the EvoEndo® Single-Use Endoscopy System by hiring additional personnel and growing inventory capacity. The company will also deploy the funding to conduct clinical and post-market surveillance studies.
Trending
- 5 doctors weigh in on the promise, limitations of Grail’s multicancer test (Medtech Dive)
- IBS Pain Closely Linked to Interrelated Daily-Life Triggers (Physicians Weekly)
- First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication (Takeda)
- Industry Voices—How physician practices can grow and succeed without the support of private equity (Fierce Healthcare)
- Blood-Based CRC Test Upgrades Improve on Precancerous Lesion Detection (Medscape)
- Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing (Lucid Diagnostics)
- How Can GI Fellowship Programs Enhance Ambulatory Training? (Yale School of Medicine)
- VIOVOC Issued U.S. Patent for Ambient Sensing Technology That Decodes Gut Microbiome Signals (Business Wire)
